These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 18043682

  • 21. Legal overprotection.
    Friedman JH.
    Med Health R I; 2004 Oct; 87(10):294. PubMed ID: 15559378
    [No Abstract] [Full Text] [Related]

  • 22. Assessing supplement safety--the FDA's controversial proposal.
    Cohen PA.
    N Engl J Med; 2012 Feb 02; 366(5):389-91. PubMed ID: 22276780
    [No Abstract] [Full Text] [Related]

  • 23. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
    DerGurahian J.
    Mod Healthc; 2007 Oct 08; 37(40):16. PubMed ID: 18018373
    [No Abstract] [Full Text] [Related]

  • 24. Drug-review deadlines and safety problems.
    Nardinelli C, Lanthier M, Temple R.
    N Engl J Med; 2008 Jul 03; 359(1):95-6; author reply 96-8. PubMed ID: 18596282
    [No Abstract] [Full Text] [Related]

  • 25. The new drug evaluation process: risk benefit ratio.
    Somberg JC.
    Am J Ther; 2005 Jul 03; 12(3):199-200. PubMed ID: 15891261
    [No Abstract] [Full Text] [Related]

  • 26. Safety surveillance in drug development: understanding the process and its implications for nephrology nursing.
    Browar S.
    Nephrol Nurs J; 2002 Apr 03; 29(2):143-50. PubMed ID: 11997949
    [Abstract] [Full Text] [Related]

  • 27. Impossible? Outlawing state safety laws for generic drugs.
    Glantz LH, Annas GJ.
    N Engl J Med; 2011 Aug 25; 365(8):681-3. PubMed ID: 21830958
    [No Abstract] [Full Text] [Related]

  • 28. Spending on postapproval drug safety.
    Ridley DB, Kramer JM, Tilson HH, Grabowski HG, Schulman KA.
    Health Aff (Millwood); 2006 Aug 25; 25(2):429-36. PubMed ID: 16522583
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Round table: Post-marketing evaluation of fertility-regulating drugs as viewed by the pharmaceutical industry.
    Hum Reprod; 1987 Apr 25; 2(3):241-63. PubMed ID: 3597744
    [No Abstract] [Full Text] [Related]

  • 31. Are novel drugs more risky for patients than less novel drugs?
    Olson MK.
    J Health Econ; 2004 Nov 25; 23(6):1135-58. PubMed ID: 15556240
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Industry reneges on postmarketing trial commitments.
    Bouchie A.
    Nat Biotechnol; 2003 Jul 25; 21(7):718. PubMed ID: 12833074
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Results of drug trials can mystify doctors through omission: some professional groups demand public listing of all test outcomes.
    Meier B.
    N Y Times Web; 2004 Jul 21; ():C1, C3. PubMed ID: 15290807
    [No Abstract] [Full Text] [Related]

  • 36. Drug review "behind the curtain": a response to Professor Struve.
    O'Reilly JT.
    Cornell Law Rev; 2008 Jul 21; 93(5):1075-90. PubMed ID: 18618971
    [No Abstract] [Full Text] [Related]

  • 37. The FDA and safety--beyond the heparin crisis.
    Laurencin CT, Nair L.
    Nat Biotechnol; 2008 Jun 21; 26(6):621-3. PubMed ID: 18536680
    [No Abstract] [Full Text] [Related]

  • 38. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM.
    Regul Toxicol Pharmacol; 2009 Nov 21; 55(2):181-7. PubMed ID: 19589365
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Canaries, coal mines and the drug supply.
    Leiden JM.
    Nat Biotechnol; 2008 Jun 21; 26(6):624-6. PubMed ID: 18536681
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.